Minerva Neurosciences (NERV) Stock Price, News & Analysis

Company Overview

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research activities have centered on conditions including schizophrenia, major depressive disorder and other neuropsychiatric diseases with significant unmet medical needs.

Minerva’s lead investigational product has been roluperidone, formerly known as MIN-101, an orally administered compound studied as a potential treatment for negative symptoms of schizophrenia. The company has also been involved in the development of other central nervous system drug candidates, including treatments designed to influence serotonin, sigma and orexin receptor pathways.

Founded in 2007 and headquartered in Waltham, Massachusetts, Minerva has conducted clinical development activities in the United States and Europe. Its programs have primarily been advanced through clinical trials and collaborations with pharmaceutical companies and research organizations. As a development-stage biotechnology company, Minerva’s operations and product portfolio have historically focused on advancing investigational therapies rather than marketing an established commercial product line.

Key Stats

• Today's Range: $2.37 to $2.50
• 50-Day Range: $2.32 to $5.43
• 52-Week Range: $2.24 to $8.80
• Volume: 121,144 shs
• Average Volume: 118,860 shs
• Market Capitalization: $114.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.33
• Consensus Rating: Hold

Minerva Neurosciences Stock Analysis - MarketRank™

Minerva Neurosciences scored higher than 31% of companies evaluated by MarketBeat, and ranked 754th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Minerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

Upside Potential

Minerva Neurosciences has a consensus price target of $10.33, representing about 330.6% upside from its current price of $2.40.

Amount of Analyst Coverage

Minerva Neurosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Minerva Neurosciences are expected to grow in the coming year, from ($0.73) to ($0.42) per share.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.19% of the float of Minerva Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Minerva Neurosciences has a short interest ratio ("days to cover") of 12.96, which indicates bearish sentiment.

Change versus previous month

Short interest in Minerva Neurosciences has recently increased by 0.59%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Minerva Neurosciences does not currently pay a dividend.

Dividend Growth

Minerva Neurosciences does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of Minerva Neurosciences is held by insiders.

Percentage Held by Institutions

34.56% of the stock of Minerva Neurosciences is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/22/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:NERV
• CIK: 1598646
• Web: www.minervaneurosciences.com
• Phone: (617) 600-7373
• Fax: N/A
• Employees: 7
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Minerva Neurosciences: $10.33
• High Price Target: $14.00
• Low Price Target: $7.00
• Potential Upside/Downside: +330.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($28.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$293.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -31.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.15
• Quick Ratio: 20.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.25) per share
• Price / Book: -0.74

Miscellaneous

• Outstanding Shares: 47,750,000
• Free Float: 46,936,000
• Market Cap: $114.60 million
• Optionable: Optionable
• Beta: -0.10